Institutional members access full text with Ovid®

Share this article on:

Influence of Adalimumab Treatment on Anastomotic Strength, Degree of Inflammation, and Collagen Formation: An Experimental Study on the Small Intestine of Rabbits

Ploug, Thomas MD*; Andersen, Kristian MD*; Hansen, Katrine MD*; Hjelmborg, Jacob PhD; Qvist, Niels DMSci

doi: 10.1097/MIB.0b013e318281007c
Original Basic Science Articles

Background: Adalimumab is a TNF-α inhibitor, which has gained wide use in the treatment of inflammatory bowel diseases. The potential detrimental effect of TNF-α inhibitors on postoperative complications such as anastomotic leakage is unknown. The aim of this study was to investigate the effect of a single therapeutic dose of adalimumab on anastomotic strength inflammation and collagen formation.

Methods: Twenty-eight female rabbits (1.8-2.2 kg) were allocated to subcutaneous injection with either adalimumab (1.5 mg/kg) (n=14) or placebo (n=14). One week after medication two separate end-to-end anastomoses were performed in the jejunum. The rabbits were killed on the third postoperative day. The anastomosis were subjected to tensile strength analysis and histopathological examination.

Results: No statistically significant differences were found between the two groups regarding maximum tensile strength, inflammation parameters and collagen formation in the anastomosis area. Multiple regression analysis showed no association between maximum tensile strength histological changes, time under anaesthesia, duration of surgery, weight gain, weight loss and number of sutures in either group.

Conclusion: We found no statistically significant effect of a single therapeutic dose of adalimumab on anastomotic strength, histological parameters or collagen formation in rabbits.

Article first published online 17 January 2013

*Odense University Hospital, Department of Clinical Pathology, Odense, Denmark

University of Southern Denmark, Department of Research in Biostatistics, Odense, Denmark

Odense University Hospital, Surgical Department A, Odense, Denmark.

Reprints: Mr. Kristian Andersen, Møgelbjergvej 1, Vodskov, 9310, Denmark (e-mail: kristiangroendalandersen@gmail.com).

Received May 11, 2012

Accepted May 15, 2012

© Crohn's & Colitis Foundation of America, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website